Trials / Recruiting
RecruitingNCT06760260
Evaluation of the Safety and Efficacy of Human CI-135 (FLT3) Targeted CAR-T Cells Injection for Subjects with Relapsed/Refractory Acute Myeloid Leukemia
A Study to Evaluate the Safety and Efficacy of CI-135 CAR-T Cell Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
- Status
- Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 7 (estimated)
- Sponsor
- Hrain Biotechnology Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study is a single-arm, open-label, dose-escalating trial to explore the safety, tolerability and pharmacokinetic/pharmacodynamics characteristics of anti human CI-135 (FLT3) CAR-T Injection , and to preliminarily observe the efficacy of the trial drug in patients with relapsed/refractory Acute Myeloid Leukemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Human Derived anti-CI135 CAR-T Injection | Autologous genetically modified anti-CI135 CAR transduced T cells |
Timeline
- Start date
- 2022-01-26
- Primary completion
- 2025-12-31
- Completion
- 2026-12-31
- First posted
- 2025-01-06
- Last updated
- 2025-01-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06760260. Inclusion in this directory is not an endorsement.